This is a rare genetic disorder affecting sugar breakdown. It causes sugars to build up in the body, leading to physical and mental health problems. It's caused by a missing enzyme and is often linked to dwarfism and hearing loss.
Every report comes from a Lived member, sent anonymously.
Have you tried Enzyme Replacement Therapy for Maroteaux-Lamy Syndrome (MPS VI)?
Maroteaux-Lamy syndrome, also called mucopolysaccharidosis type VI (MPS VI), is a rare inherited condition in which the body cannot properly break down certain large sugar molecules called glycosaminoglycans (GAGs). These molecules gradually build up inside cells throughout the body, causing tissues to thicken, stiffen and scar. Over time this affects the bones and joints, heart valves, airway, eyes and ears. Babies with MPS VI usually look healthy at birth, and signs typically appear in early childhood. Common features include slowed growth and short stature, stiff joints that limit movement, a curved or misshapen spine, coarse facial features, an enlarged tongue, liver and spleen, hernias, clouding of the clear front surface of the eye, hearing loss and frequent ear and airway infections. Unlike several other types of MPS, MPS VI does not affect intelligence. The condition varies widely. Some people have a rapidly progressing form that causes serious problems in childhood, while others have a slowly progressing form that may not be recognized until later and allows a longer life with fewer limitations. Many people fall somewhere in between.
MPS VI is caused by changes (variants) in the ARSB gene, which carries the instructions for an enzyme called arylsulfatase B. This enzyme normally works inside lysosomes, the cell's recycling compartments, to break down GAGs. When the enzyme is missing or works poorly, GAGs accumulate, enlarging cells and triggering inflammation and tissue damage. Which gene changes a person has helps explain why the severity differs so much from one person to another. The condition is inherited in an autosomal recessive pattern: a child is affected only when they receive a nonworking copy of the gene from both parents. Parents who each carry one copy are usually healthy and often have no family history of the disease. Nothing a parent did or did not do during pregnancy causes MPS VI. Families who know they carry the gene can talk with a genetic counselor about testing for relatives and options in future pregnancies.
MPS VI is usually suspected when a child shows a combination of features such as slowed growth, joint stiffness, characteristic changes on bone X-rays, coarse facial features or clouded corneas. A urine test showing high levels of GAGs, particularly a type called dermatan sulfate, points toward an MPS disorder, but it cannot confirm the diagnosis on its own. Confirmation comes from an enzyme test showing very low arylsulfatase B activity in white blood cells or skin cells, genetic testing that finds two disease-causing changes in the ARSB gene, or both. Because MPS VI is rare and its early signs overlap with other skeletal and storage conditions, diagnosis is often made by a specialist in genetic or metabolic diseases. After diagnosis, a baseline set of assessments maps how the condition is affecting the body. This often includes heart ultrasound (echocardiogram), breathing tests and an overnight sleep study, spine X-rays and magnetic resonance imaging (MRI), hearing and eye examinations, and walking tests that measure endurance.
There is no cure for MPS VI, but treatment can slow some of its effects and preserve function. The main disease-specific treatment is enzyme replacement therapy with galsulfase (Naglazyme), a lab-made version of the missing enzyme. It is given as an intravenous infusion once a week, usually lasting at least four hours, and is meant to continue long term. Expert guidance recommends starting as soon as possible after diagnosis. Galsulfase improves walking and stair-climbing endurance and lung function, and when started in young children it may help growth and slow the worsening of heart valve disease. Its limits matter for planning: it does not appear to clear corneal clouding, and it has little effect on bone and joint deformities once they have developed. Infusion reactions such as fever, rash or chills are common and are usually managed with premedication and slower infusions. The medicine also carries a warning for serious allergic reactions, including anaphylaxis, which can occur early or after years of treatment, so infusions begin in a monitored medical setting. Because many parts of the body are involved, care is shared by a team that may include metabolic, heart, lung, ear-nose-throat, eye, spine, orthopedic and hand specialists, along with physical and occupational therapists. Common interventions include removal of tonsils and adenoids or a CPAP machine (continuous positive airway pressure, which keeps the airway open with a mask during sleep) for sleep apnea, surgery to relieve pressure on the spinal cord or the nerves of the wrist (carpal tunnel syndrome), corrective bone and hip surgery, heart valve replacement and corneal transplants. Walking aids, hand splints and adaptive tools suggested by therapists can make daily tasks easier. Stem cell (bone marrow) transplant has been used in a small number of people and can raise enzyme levels, but the evidence is limited and the procedure carries serious risks, including death. It is considered case by case at experienced transplant centers.
MPS VI is a lifelong, progressive condition, and the outlook depends largely on how quickly it progresses. Without treatment, people with the rapidly progressing form may live only into late childhood or adolescence, while people with slower forms usually live into adulthood, though often with a shortened life expectancy. Heart disease and airway obstruction are the most common serious complications. Because thinking and learning are not affected, many people with MPS VI attend school, work and live full social lives. The day-to-day challenges tend to be physical: limited stamina, stiff joints and reduced hand dexterity, short stature, pain, and gradual changes in vision and hearing. Weekly infusions lasting several hours are also a significant, ongoing time commitment. Regular monitoring is a central part of life with MPS VI. Heart, lung, spine, eye, ear and endurance checks are repeated on a schedule, often every six to twelve months, so that problems such as spinal cord narrowing or worsening valves are found before they cause lasting harm. Anesthesia deserves special planning. A narrowed airway and an unstable neck can make sedation and breathing tubes risky, so surgeries and scans needing sedation should be done by teams experienced with MPS at centers with intensive care. When possible, combining procedures can reduce the number of anesthetics.
See a doctor if a child has a combination of slowed growth, stiff joints, frequent ear or chest infections, hernias, clouded eyes or coarsening facial features. For anyone already diagnosed, raise loud snoring, pauses in breathing at night, morning headaches, declining stamina, hand numbness or worsening hearing or vision at the next visit, or sooner if they are changing quickly. Contact the care team promptly about new weakness, numbness or tingling in the arms or legs, clumsiness, or difficulty walking, since these can signal pressure on the spinal cord in the neck. Tell any doctor planning sedation or surgery about the diagnosis well in advance. Call 911 for trouble breathing, swelling of the face or throat, or fainting during an infusion or in the day after it, as these can be signs of a severe allergic reaction.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Maroteaux-Lamy Syndrome (MPS VI) is like, what's helped you, or ask the community a question.